Myelofibrosis - Research unit

-Hemogenic potential of circulating endothelial cells in patients with primary myelofibrosis. 

-Identification, characterization and role of Myeloid Derived Suppressor Cells (MDSCs) in the pathogenesis of myelofibrosis.

-Mesenchymal stem cells-derived microvescicles: cross-talk with hematopoietic progenitor cells and bone marrow microenvironment. 

-Identification of somatic and germline mutations in the peripheral blood cells of patients and correlation with disease phenotype and prognosis.

• Barosi, Rosti, Bonetti, Campanelli, Carolei, Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis, PLoS ONE, 2012
• Barosi, Klersy, Villani, Bonetti, Catarsi, JAK2 V617F allele burden ≥50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy, Leukemia, 2016
• Poletto, Rosti, Villani, Catarsi, Carolei, A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation, Blood, 2012
• Barosi, Rosti, Catarsi, Villani, Abbà, Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis, Leukemia, 2021
• Barosi, Rosti, Massa, Campanelli, Villani, Clonal Megakaryocyte Dysplasia with Normal Blood Values Is a Distinct Myeloproliferative Neoplasm, Acta Haematologica, 2022

 -Fluorescence-activated cell sorting and in vitro culture of hematopoietic and endothelial progenitor cells;

European Commission, Italian Ministry of University and Research, Italian Ministry of Health, AXA Research Fund, Fondazione Cariplo. 

Italian Institute of Health, Italian Society of Public Health, European Public Health Association, London School of Hygiene and Tropical Medicine, Harvard School of Public Health.